Back to search results

Understanding Sex Differences in Blood Vessel Response to Low Oxygen and Obesity

This study is looking at how blood vessels react to low oxygen (hypoxia) in people with and without obesity, focusing on differences between men and women. Researchers will use drugs like Propranolol Hydrochloride, Isoproterenol, Phentolamine Mesylate, and Norepinephrine, delivered directly into the arm, to see how they affect blood vessel widening (vasodilation). The main goal is to measure changes in how easily blood flows through the forearm after these drugs are given. You might be able to join if you are between 18 and 45 years old, have a BMI (Body Mass Index) greater than 18 kg/m2, and do not have certain health conditions like pregnancy, sleep apnea, or heart disease. The study aims to enroll 72 participants. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 72 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured as the change from baseline to the last 1-minute of drug infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05219799

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

Recruiting
EARLY_PHASE1Ages 18–45InterventionalBasic science
University of Missouri-Columbia
~72 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:Propranolol HydrochlorideIsoproterenolPhentolamine MesylateNorepinephrine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in forearm vascular conductance with intra-arterial drug infusion
Measured over Change from baseline to last 1-minute of drug infusion

Conditions

Obesity
Vasodilation
Healthy

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Jacqueline Limberg, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Missouri-Columbia

Who to contact

Jacqueline K Limberg, Ph.D.
[email protected]
5738822544
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI \>18 kg/m2

Exclusion

Pregnancy, breastfeeding
Diagnosed sleep apnea or AHI \>10 events/hr
Current smoking/Nicotine use
Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
Nerve/neurologic disease
Cardiovascular, hepatic, renal, respiratory disease
Blood pressure ≥140/90 mmHg
Diabetes, Polycystic ovarian syndrome
Communication barriers
Prescription medications, Sensitivity to lidocaine

What this trial measures

  • Change in forearm vascular conductance with intra-arterial drug infusionChange from baseline to last 1-minute of drug infusion

    Vascular conductance is an index of vascular tone and is measured using a technique called venous occlusion plethysmography.